Highly Purified Scavenger Receptor Class B, Type I
Reconstituted into Phosphatidylcholine/Cholesterol Liposomes Mediates
High Affinity High Density Lipoprotein Binding and Selective Lipid
Uptake*
Bin
Liu
and
Monty
Krieger§
From the Department of Biology, Massachusetts Institute of
Technology, Cambridge, Massachusetts 02139
Received for publication, May 1, 2002, and in revised form, July 9, 2002
 |
ABSTRACT |
The murine class B, type I scavenger receptor
mSR-BI is a high and low density lipoprotein (HDL and LDL) receptor
that mediates selective uptake of cholesteryl esters. Here we describe
a reconstituted phospholipid/cholesterol liposome assay of the binding
and selective uptake activities of SR-BI derived from
detergent-solubilized cells. The assay, employing lysates from
epitope-tagged receptor (mSR-BI-t1)-expressing mammalian and insect
cells, recapitulated many features of SR-BI activity in intact cells,
including high affinity and saturable 125I-HDL
binding, selective lipid uptake from [3H]cholesteryl
ether-labeled HDL, and poor inhibition of HDL receptor activity by LDL.
The novel properties of a mutated receptor (Q402R/Q418R, normal
LDL binding but loss of most HDL binding) were reproduced in the assay,
as was the ability of the SR-BI homologue CD36 to bind HDL but not
mediate efficient lipid uptake. In this assay, essentially
homogeneously pure mSR-BI-t1, prepared by single-step immunoaffinity
chromatography, mediated high affinity HDL binding and efficient
selective lipid uptake from HDL. Thus, SR-BI-mediated HDL binding and
selective lipid uptake are intrinsic properties of the receptor that do
not require the intervention of other proteins or specific cellular
structures or compartments.
 |
INTRODUCTION |
The LDL1 receptor
pathway for the delivery of lipoprotein cholesterol to cells involves
clathrin-coated pit-mediated endocytosis and subsequent lysosomal
degradation of the entire LDL particle (1). Almost 20 years ago a
strikingly different mechanism for the cellular uptake of lipoprotein
cholesterol, called selective cholesterol uptake, was identified during
the analysis of HDL metabolism in vivo (2, 3). Selective
cholesterol uptake from HDL and other lipoproteins does not involve
endocytosis and subsequent degradation of the entire lipoprotein
particle (2, 3; reviewed in Refs. 4 and 5). In the case of HDL, the
lipoprotein binds to the cell surface and transfers its cholesteryl
esters to the cell, and then the lipid-depleted HDL particle
dissociates from the cell and can re-enter the circulation.
The HDL receptor SR-BI (scavenger receptor, class B, type I) was the
first cell surface receptor to be shown to mediate physiologically relevant selective lipid uptake (6-8; reviewed in Ref. 5). In
vivo studies have established that SR-BI critically influences HDL
structure and metabolism and apparently plays an important role in the
transport of cholesterol from peripheral tissues to the liver for
recycling or biliary excretion (5, 7-12). This probably accounts for
the ability of SR-BI to protect against atherosclerosis in murine
models (9, 13-15). Recent studies have established that expression of
SR-BI in mice is normally required for red blood cell development (16)
and female fertility (9, 17) and can prevent the development of
myocardial infarctions, cardiac dysfunction, and premature death in
apoE-deficient mice (18).
In vitro studies have shown that SR-B can bind and mediate
lipid uptake from LDL as well as HDL (6, 19-22). Strikingly, HDL
competes efficiently for LDL binding, whereas LDL is a poor competitor
of HDL binding (6, 23). SR-BI also can facilitate the efflux of
unesterified cholesterol from cultured cells (24, 25), although the
physiologic significance of this is not certain. Several studies
support the proposal (26) that SR-BI-mediated transport of lipids
between cells and lipoproteins involves two sequential steps: 1)
productive lipoprotein binding and 2) binding-dependent, yet distinct, SR-BI-mediated lipid transfer (25-29). It has not yet
been determined if SR-BI-mediated selective lipid uptake occurs only at
the cell surface, or in some intracellular compartment followed by
retroendocytosis (secretion) of the lipid-depleted lipoprotein, or both
(30-32; reviewed in Refs. 4 and 5).
A particularly important question regarding the mechanism of SR-BI
activity has been: does SR-BI require the participation of one or more
other proteins to mediate either ligand binding, lipid transport, or
both, or are these activities autonomous properties of SR-BI
(independent of other proteins)? This question has arisen, in part,
because of the multiple and complex activities of SR-BI (5). A direct
approach for studying the autonomous properties of SR-BI and its
mechanism of action is to examine in an in vitro system the
activity of the receptor purified away from other proteins. Here we
describe an in vitro reconstituted liposome assay for SR-BI-mediated ligand binding and selective lipid uptake that reflects
many of the characteristics of SR-BI activity in intact cells. This
assay, effective with total cell lysates as well as highly purified
protein, was used to show that, in the absence of other proteins, SR-BI
can bind HDL and LDL and mediate efficient selective cholesteryl ether
uptake from HDL.
 |
EXPERIMENTAL PROCEDURES |
Materials
Human high density lipoprotein (HDL), human low density
lipoprotein (LDL), 125I-labeled HDL,
125I-labeled LDL,
1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanime perchlorate
(DiI)-labeled HDL (DiI-HDL), and human lipoprotein-deficient serum were
prepared as previously described (6, 19). The phCD36 expression vector
(33) was a generous gift from B. Seed (Massachusetts General Hospital).
The KKB-1 antibody was a generous gift from Karen Kozarsky (25). The
1D4 antibody was obtained from the ATCC. The mixture of complete
protease inhibitors was purchased from Roche Molecular Biochemicals.
All other reagents were purchased from standard suppliers or obtained
as indicated below. Cell culture supplies were purchased from
Invitrogen, Irvine Scientific, or JRH Biosciences. The peptide
TETSQVAPA was prepared in the biopolymer laboratory at Massachusetts
Institute of Technology and was a gift from the G. Khorana laboratory.
[3H]CE-HDL Preparation
[3H]Cholesteryl ether
([3H]CE)-labeled HDL ([3H]CE-HDL) was
prepared according to the procedure of Rodrigueza et al.
(34) with minor modifications. The labeled [3H]CE-HDL was
isolated by ultracentrifugation (225,000 × g) and filtered through a 0.22-µm membrane, and the protein concentration was determined using the method of Lowry et al. (35).
Construction of Expression Vectors
Mammalian Expression Vectors--
mSR-BI cDNA was amplified
from pmSR-BI (6) by PCR using the primers BL5,
5'-GACACTGGTACCGATATCACGCGGACATGGGCGGCAGCTCCAG-3', and BL3,
5'-CTGTCACTCGAGGTCGACTTAGGCAGGCGCCACTTGGCTGGTCTCTGTTAGCTTGGCTTCTTGCAGCACCGTG-3' that resulted in a cDNA encoding a full-length mSR-BI protein that contained a 9-amino acid (TETSQVAPA) C-terminal extension representing the C terminus of bovine rhodopsin as an epitope tag. The
protein product of this cDNA is designated "mSR-BI-t1'." The
PCR product was treated with restriction endonucleases KpnI and XhoI, and the KpnI/XhoI fragment
was cloned into the mammalian expression vector pcDNA3(+)
(Invitrogen) that includes an internal neomycin resistance marker for
selection in mammalian cells. The ligation product was used to
transform Escherichia coli cells, and the plasmid DNAs of
selected clones were isolated and sequenced. One of these with the
expected sequence was designated pmSR-BI-t1. The mSR-BI-t1 cDNA was
then reconstructed into an expression plasmid (36) using an
SalI and EcoRV restriction fragment from
pmSR-BI-t1. This plasmid was designated pACmSR-BI-t1 and was used for
the generation of the stable cell line HEK[mSR-BI-t1] (see below).
Sf21 Expression Vectors--
Three receptors were
expressed in Sf21 cells at high levels using the Bac-To-Bac
baculovirus expression system (Invitrogen). These were mSR-BI-t1, a
double-substitution mutant of mSR-BI-t1 (arginines in place of the
glutamines at positions 402 and 418, designated
"402R/418R"), which retains most of the LDL
but little of the HDL receptor activity of the parent receptor (23),
and human CD36. Briefly, pFastBac donor plasmids were constructed by
ligation of the restriction endonuclease XhoI- and
EcoRI-digested fragments of pmSR-BI-t1 or the PCR products
for CD36 or mutant mSR-BI-t1 into
XhoI/StuI-treated pFastBac vector (Invitrogen).
The template and PCR primers for CD36 were: phCD36 (33),
5'-CGAGGATATCGGCAAGAAACAGGTGC-3' and 5'-GCAGCTCGAGGTCACAAGTACATC-3'. The template and PCR primers for the
mutant SR-BI-t1 402R/418R were: VM54 (23),
5'-GACACTGGTACCGATATCACGCGGACATGGGCGGCAGCTCCAG-3', and
5'-CTGTCACTCGAGGTCGACTTAGGCAGGCGCCACTTGGCTGGTCTCTGTTAGCTTGGCTTCTTGCAGCACCGTG-3'. Recombinant bacmids were generated by transformation of DH10Bac E. coli cells with the cloned donor plasmids, selection of
antibiotic (kanamycin/tetracycline/gentamicin)-resistant colonies, and
isolation of plasmid DNA from the cultures of the selected colonies
(37).
Mammalian Cell Culture and Transfection
The mammalian cell lines HEK293S (38) (gift from P. Reeves and
G. Khorana) and COS M6 were maintained attached to the substratum in
medium A (Dulbecco's modified Eagle's medium/Ham's F-12 medium (1:1)
supplemented with 50 units/ml penicillin, 50 µg/ml streptomycin, 2 mM glutamine (Invitrogen), and 10% fetal bovine serum (JRH
Biosciences)) in a humidified 95% air/5% CO2 incubator.
For suspension culture, HEK293S cells were grown with constant gentle
stirring at 20-40 rpm in spinner bottles in medium B (HBGro medium
(Irvine Scientific) supplemented with 50 units/ml penicillin, 50 µg/ml streptomycin, 2 mM glutamine, and 10% fetal bovine
serum) at 37 °C in a humidified incubator in 5%
CO2/95% air. For suspension growth, cells were inoculated
at 1.2 × 105 cells/ml in 500 ml of medium B and
incubated for 5-7 days without changing the medium. Cells were
harvested either after reaching confluence on dishes by treatment with
trypsin/EDTA (JRH Biosciences) or after 6 days of growth in suspension.
For transient transfections, 1.5 × 106 COS M6 cells
were seeded in 10-cm dishes in medium A without antibiotics and grown
at 37 °C overnight. The cells were treated with 10 µg per plate of DNA (pmSR-BI-t1 or the "empty" vector pcDNA3 without an
expression cassette insert as a control) using the LipofectAMINE
(Invitrogen) method according to the manufacturer's recommendations.
The cells were grown in medium A for an additional 2 days, and then
receptor activity assays were performed. Briefly, 24 h
post-transfection, the cells were washed with PBS, harvested with
trypsin/EDTA, and plated in 1 ml/well of medium A at 150,000 cells/well
in 24-well plates. The receptor activity of the cells was analyzed
48 h post-transfection.
A stable cell line expressing high levels of mSR-BI-t1,
HEK[mSR-BI-t1] (clone 7), was established as follows: HEK293S cells were transfected with the pACmSR-BI-t1 vector using the LipofectAMINE method and maintained for 2 weeks in medium A supplemented with 0.8 mg/ml G418. Individual colonies were isolated by screening for their
abilities to take up the fluorescent dye DiI from DiI-HDL (10 µg of
protein/ml, 2 h at 37 °C) with an inverted fluorescence microscope and by flow cytometry as previously described (26).
Insect (sf) Cell Culture and Baculovirus Expression
The Sf21 cells (gift from K. Cha, E. Getmanova, and G. Khorana) were maintained in SFM II medium (Invitrogen) in suspension at
27 °C in a humidified incubator and passaged when the viable cell
count reached 2 × 106 cells/ml. The recombinant
bacmid DNAs described above, encoding mSR-BI-t1, the
402R/418R mutant form of mSR-BI-t1 and CD36,
were used to transfect Sf21 cells in T25 flasks using the
Bac-to-Bac expression system (Invitrogen) according to the
manufacturer's recommendations. After growth of the transfected
Sf21 cells for 5 days at 27 °C in Grace's medium, the media
were collected as the recombinant baculovirus particle stocks and used
for infection of Sf21 cells (procedures carried out according to
the manufacturer's recommendations). The infected cells were grown in
Grace's medium for 72-168 h and harvested by centrifugation. High
level expression of the proteins was verified by SDS-PAGE, and
immunoblotting analysis of cell extracts, prepared as described below,
using polyclonal anti-SR-BI antibody KKB-1 or anti-CD36 antibody (BD
PharMingen). Cells also were infected with an "empty" vector to
permit generation of receptor-free cell extract controls. Cell lysates
were prepared (see below) and used for immunoblot analysis and liposome
reconstitution studies.
Determination of Receptor Cell Surface Expression and
Function in Intact Mammalian Cells
Cell Surface Expression--
Transiently transfected COS cells
were incubated with polyclonal antisera (KKB-1) against mSR-BI, washed,
incubated with fluorescein-conjugated goat anti-rabbit IgG (Amersham
Biosciences), washed again, and harvested with trypsin, and receptor
cell surface expression was determined by flow cytometry as previously
described (23).
Cell Function Analysis--
The 125I-HDL binding
assay was performed as previously described (6). The
[3H]CE-HDL cell association assay was similar to the
125I-HDL binding assay, except for the following changes:
the NaOH cell lysis step was preceded by the addition of 1 ml of
isopropanol at room temperature for 30 min to extract the incorporated
[3H]cholesteryl ether from the cells. Radioactivity in
the isopropanol extract was measured using a liquid scintillation
analyzer (Packard Instrument Co., Meriden, CT). The amount of
[3H]cholesteryl ether associated with the cells (or
liposomes in the assay described below) is expressed as the equivalent
amount of [3H]CE-HDL protein (nanograms). This standard
method of presenting the data (e.g. see Ref. 26) permits a
direct comparison of the relative amounts of 125I-HDL
binding and lipid uptake from [3H]CE-HDL and clearly
indicates the extent of selectivity of the lipid uptake process.
Preparation of Total Cell Lysates
HEK[mSR-BI-t1] and untransfected HEK293S cells were plated at
1-2 × 105 cells/plate in 10-cm plates and grown in
15 ml of medium A for 3-4 days. When the cells were confluent,
the plates were washed twice with PBS, and the cells were harvested by
scraping with a rubber policeman and concentrated into a pellet by
centrifugation at 4 °C at 1,460 × g for 20 min in
an SS34 rotor in a Sorvall RC-5B centrifuge (DuPont Instruments). The
cell pellets were dissolved by adding 1 ml of lysis buffer A (1.5%
(w/v) octyl glucoside and protease inhibitors (1×) in PBS) per
0.1 g (wet weight) of pellet and incubating at 4 °C for 30 min
with gentle mixing. The lysates were clarified by centrifugation at
11,951 × g using an SS34 rotor for 20 min at 4 °C,
and the supernatants were collected and used as total cell lysates.
Protein concentration was determined by the DC protein assay (Bio-Rad)
and was typically 1-2 mg/ml. The same procedure was used to prepare
lysates from Sf21 cells.
Immunoaffinity Purification of mSR-BI-t1
mSR-BI-t1 was purified by immunoaffinity chromatography using a
modification of the procedure of Reeves et al. (38).
Briefly, 1.5 g (wet weight) of HEK[mSR-BI-t1] cells were
incubated with 13 ml of lysis buffer A at 4 °C for 30 min. The
solution was clarified by centrifugation (4 °C, 11,951 × g, 20 min), and filtration (0.45 µM Durapore
membrane (Millipore)). The subsequent purification steps were carried
out at room temperature. Five milliliters of the extract were loaded
onto a 0.3-ml anti-C-terminal 1D4 antibody-Sepharose column, which was
pre-equilibrated with lysis buffer A. After washing with 50 column-volumes of lysis buffer A, and 10 column-volumes of column
buffer A (10 mM Tris (pH 6.0), 1.5% octyl glucoside, and
protease inhibitors), bound proteins were eluted with 2 ml of elution
buffer (column buffer A containing 100 µM of the
peptide epitope (TETSQVAPA), 0.3-ml fractions). Samples (10 µl) were fractionated by SDS-PAGE and analyzed by either silver
staining or immunoblotting with the anti-SR-BI antibody KKB-1. The
purified protein was stored in the elution buffer at
20 °C.
Liposome Preparation
The preparation of multilamellar vesicles was carried out
according to Schneider et al. (39) with minor modifications.
Briefly, egg yolk L-
-phosphatidylcholine (Avanti) and
cholesterol (Sigma Chemical Co.) (molar ratio of 5:1) in ether were
dried and resuspended at 2 mg/ml in 50 mM Tris buffer (pH
6.0). Then 0.5 ml of the suspension and 2.4 ml of buffer B (50 mM Tris, pH 6.0, 150 mM NaCl, 2 mM CaCl2) containing either 100 µg of detergent-solubilized
cell lysate or 2 µg of detergent-solubilized purified mSR-BI-t1 were mixed, precipitated by 0.6 volume of ice-cold acetone, and the precipitate was recovered by centrifugation (4 °C at 30,596 × g, 20 min). The liposomes were resuspended in 300 µl of
buffer C (20 mM Tris, pH 8.0, 1 mM
CaCl2, 20 mM NaCl, and protease inhibitors).
Filter Binding Assay
Liposomes (8 µl) were diluted with 12 µl of assay buffer (20 mM Tris, pH 8.0, 2 mM CaCl2, 80 mg/ml fat-free bovine serum albumin (Sigma), and protease inhibitors
(1×)) and the indicated amounts of 125I- HDL or
[3H]CE-HDL (usually 10 µg of protein/ml) in the
presence (single incubations) or absence (duplicate incubations) of a
40-fold excess of unlabeled HDL. The mixture was incubated at 37 °C
for 2 h unless otherwise noted, and the liposomes with bound
125I-HDL were isolated by filtration (39) using 0.45 µM nitrocellulose membranes and a multifilter filtration
manifold (Millipore, Milford, MA). Briefly, the filters in the manifold
were moistened with wash buffer (20 mM Tris, pH 8.0, 50 mM NaCl, 20 µM CaCl2, and 1 mg/ml
fatty acid-free bovine serum albumin), the assay mixture was filtered
at room temperature and then the filters were washed three times with
wash buffer. The amounts of 125I bound were measured with a
gamma counter (LKB-Wallac, Finland). To measure 3H, the
filters were added to 4 ml of Hydrofluor scintillation fluid (National
Diagnostics) and radioactivity was measured using a liquid
scintillation analyzer (Packard Instrument Co., Meriden, CT).
 |
RESULTS |
The two goals of this study were 1) to develop an in
vitro reconstituted liposome assay of SR-BI-mediated ligand
binding and lipid uptake and 2) to use the assay to determine if highly
purified SR-BI required the cooperation of other proteins to mediate
HDL binding and selective lipid uptake or if it could do so
independently of other proteins. To address the later goal, we
developed a modification of the method of Reeves et al.
(38), developed for the analysis of rhodopsin, to isolate essentially
homogeneously pure and functional mSR-BI containing an exogenous
epitope tag.
Comparison of Binding and Uptake Activities of Cells Transfected
with Plasmid DNA of Wild-type and Tagged mSR-BI--
To facilitate
isolation of pure mSR-BI protein for reconstitution into liposomes, we
slightly modified the approach described by Reeves, Thurmond, and
Khorana (38) for the generation and purification of recombinant bovine
rhodopsin from transfected mammalian cells. Reeves et al.
(38) expressed bovine rhodopsin in HEK293S cells and purified the
detergent-solubilized protein using monoclonal antibody affinity
purification and epitope peptide elution. The anti-rhodopsin antibody
1D4 recognizes the C-terminal 9-amino acid peptide from rhodopsin (40).
For the synthesis and purification of mSR-BI, we constructed a
mammalian cell expression vector, pmSR-BI-t1, that encodes a chimeric
protein (mSR-BI-t1) containing the full-length mSR-BI and, at its C
terminus, the C-terminal epitope-tag TETSQVAPA from bovine rhodopsin.
To determine if epitope tagging interfered with the activity of the
receptor, we transiently transfected COS M6 cells with expression
vectors encoding either wild-type mSR-BI (COS[mSR-BI]),
epitope-tagged mSR-BI-t1 (COS[mSR-BI-t1]), or an empty vector
(pcDNA) control (COS[control]) and measured the two best defined
activities of SR-BI (5): binding of 125I-HDL and uptake of
cholesteryl ether from [3H]CE-HDL. The values for
receptor-specific binding or lipid uptake are defined as the
differences between total binding or uptake and the values determined
in the presence of a 40-fold excess of unlabeled ligand (nonspecific
values). The lipid uptake data are presented as
[3H]CE-HDL protein equivalents (nanograms of
[3H]CE-HDL protein that contain the amount of
[3H]cholesteryl ether associated with the cells). Fig.
1 shows that the specific
125I-HDL binding (panel A) or
[3H]cholesteryl ether uptake (panel C) values
for mSR-BI and mSR-BI-t1 were similar. The relative levels of surface
expression of the wild-type and tagged receptors were determined using
an anti-SR-BI antibody (KKB-1) and quantitative flow cytometry (25).
There was a somewhat higher level of expression of the tagged receptor (1.2-fold). When the 125I-HDL binding and
[3H]cholesteryl ether uptake values for the wild-type
receptor were normalized to account for this difference, the binding
and lipid uptake curves for the two receptors were virtually identical
(Fig. 1, B and D). The ratios of the maximal
[3H]CE-HDL uptake/125I-HDL binding, expressed
as equivalent ng of HDL protein/mg of cell protein, were 47 and 44, respectively, clearly showing that both receptors mediated selective
lipid uptake. Therefore, the epitope tagging at the C terminus of
mSR-BI did not appear to alter the key activities of mSR-BI in
transfected COS cells, and this tagged mSR-BI should be useful for the
isolation of purified SR-BI (see below) for studying its activity in a
reconstituted system.

View larger version (37K):
[in this window]
[in a new window]
|
Fig. 1.
125I-HDL binding (A
and B) and [3H]CE uptake from
[3H]CE-HDL (C and D) by
COS cells expressing wild-type mSR-BI or the C-terminal epitope-tagged
mSR-BI-t1. COS M6 cells were transiently transfected with
expression vectors for mSR-BI, mSR-BI-t1 (mSR-BI with a rhodopsin
epitope tag incorporated as a C-terminal extension), or the control
"empty" vector pcDNA. Two days later, the cells were incubated
for 2 h at 37 °C with the indicated concentrations of either
125I-HDL or [3H]CE-HDL in the presence
(single determinations) or absence (duplicate determinations) of a
40-fold excess of unlabeled HDL. Specific 125I-HDL binding
(A) and [3H]CE uptake (C) were
determined as described under "Experimental Procedures." The
relative levels of cell surface expression of mSR-BI and mSR-BI-t1 were
determined using the polyclonal anti-mSR-BI antibody KKB-1 by flow
cytometry as described under "Experimental Procedures." The values
for the binding and lipid uptake by the mSR-BI-expressing cells were
corrected to account for the 1.2-fold difference in surface expression
relative to that of the mSR-BI-t1-expressing cells and are shown in
C and D.
|
|
Reconstituted Liposome Assay for the Cell-free Analysis of SR-BI
Function--
We have developed a reconstituted liposome filter
binding assay for measuring the binding of 125I-HDL and the
uptake of [3H]cholesteryl ether from
[3H]CE-HDL mediated by SR-BI derived from
detergent-solubilized cultured cells based on the LDL receptor binding
assay of Schneider et al. (39) (see "Experimental
Procedures"). In brief, phosphatidylcholine/cholesterol vesicles were
prepared using detergent-solubilized whole cell lysates or
detergent-solubilized purified receptor protein. After incubation with
radiolabeled lipoprotein (standard conditions: 5-10 µg of protein/ml
of lipoprotein for 2 h at 37 °C, variations indicated below),
the liposome-associated radioactivity was determined by ultrafiltration
and counting. Standard controls included: preparation of liposomes
either with lysates from cells that do not express recombinant receptor
or without added cell lysate or purified receptor; and incubation with
a 40-fold excess of unlabeled lipoprotein to compete for the specific
binding of the ligands to the receptor. The nonspecific background
binding of 125I-HDL varied from 19 to 50% of the total
binding and appeared to depend critically on the quality of the
preparation, e.g. extent of radiolytic decomposition of the
HDL, which depends on the age and specific activity of the preparations
and can occur rapidly (41). The absolute values for binding and lipid
uptake constants (apparent Kd and
Bmax (binding maximum) and
Umax (uptake maximum)) also varied somewhat
between different receptor preparations and depended on the quality of
the radiolabeled lipoprotein (41).
Validation of the Reconstituted Liposome Assay--
The
reconstituted liposome assay was initially validated using cell lysates
from insect cells (Sf21) expressing high levels of tagged
receptor (not shown) due to infection with a baculovirus encoding
mSR-BI-t1. Previous studies have shown that insect cells can express on
their surfaces functional mammalian SR-BI (42, 43). Fig.
2A shows the ligand
concentration dependence of the binding of 125I-HDL
(squares) and the uptake of [3H]cholesteryl
ether from [3H]CE-HDL (circles) by
mSR-BI-t1-containing insect cell lysate-reconstituted liposomes
(open symbols) and control liposomes prepared with lysates from cells infected with baculovirus without the insertion (control, filled triangles). Specific 125I-HDL binding to
the mSR-BI-t1-containing liposomes (open squares) was high
affinity (apparent Kd ~ 21 µg of protein/ml, similar to that seen in mSR-BI-expressing mammalian cells (6, 41)) and
saturable (Bmax ~ 15 ng of protein/assay),
whereas there was very little specific binding to the
mSR-BI-t1-negative control liposomes (filled triangles).
Similar results were obtained for the uptake of
[3H]cholesteryl ether from [3H]CE-HDL
(open circles, apparent Kd ~ 11 µg of
protein/ml, Umax ~ 106 ng of protein/assay);
the maximal value for lipid uptake was 7-fold greater than that for
binding, indicating selective uptake.

View larger version (20K):
[in this window]
[in a new window]
|
Fig. 2.
125I-HDL binding and
[3H]CE-HDL uptake by liposomes reconstituted with insect
(Sf21) cell lysates. Sf21 cells were infected with
baculoviruses encoding mSR-BI-t1 (open symbols,
A), human CD36 (filled squares and
circles, B), or no receptor (empty virus,
filled triangles, both panels) and grown at
27 °C for 6 days. Cell lysates in 1.5% octyl glucoside lysis buffer
were reconstituted into liposomes as described under "Experimental
Procedures." The liposomes were incubated with 125I-HDL
or [3H]CE-HDL at the indicated concentrations at 37 °C
for 3 h in the presence (single determinations) or absence
(duplicate determinations) of a 40-fold excess of unlabeled HDL,
isolated, and washed by filtration, and the amounts of
specific125I-HDL binding and [3H]cholesteryl
ether uptake were determined as described under "Experimental
Procedures." Error bars represent the range of variation
in duplicate determinations. The nonspecific background values for
125I-HDL binding ranged between 19 and 28% (mSR-BI-t1) and
29 and 45% (CD36) of the total binding. The values for the no receptor
lysates were very low and overlap for specific125I-HDL
binding and [3H]cholesteryl ether uptake (broken
lines). Panel C shows with an expanded scale the
binding of 125I-HDL to the liposomes containing mSR-BI-t1
(open squares) and CD36 (filled squares).
|
|
Fig. 3 shows the time dependence of
125I-HDL binding (open squares) and
[3H]cholesteryl ether uptake from
[3H]CE-HDL (open circles) by
mSR-BI-t1-containing insect cell lysate-reconstituted liposomes at
37 °C. The 125I-HDL binding reached a steady state after
about 1 h, whereas the [3H]cholesteryl ether uptake
increased until approximately 3 h of incubation. Similar
differences in the kinetics of SR-BI-mediated HDL binding and lipid
uptake have been observed in intact cultured cells (6). There was
little binding or lipid uptake by the receptor-negative control
liposomes (solid triangles). Fig.
4 shows the temperature dependence of
125I-HDL binding and [3H]cholesteryl ether
uptake from [3H]CE-HDL (10 µg of protein/ml) by
mSR-BI-t1-containing insect cell lysate-reconstituted liposomes. The
value for 125I-HDL binding at 0 °C was somewhat lower
(79%) than that at 37 °C (100%), whereas there was a more
substantial reduction in [3H]cholesteryl ether uptake at
0 °C (25%) compared with that at 37 °C (100%). It has
previously been noted that SR-BI-mediated binding of HDL (23, 34) and
selective uptake (34) are lower at 4 °C than at 37 °C and that
the temperature sensitivity of selective uptake is greater than that of
HDL binding (34).2

View larger version (23K):
[in this window]
[in a new window]
|
Fig. 3.
Kinetics of 125I-HDL association
with and [3H]cholesteryl ether uptake by liposomes
reconstituted with mSR-BI-t1-expressing insect (Sf21) cell
lysates. Sf21 cells were infected with baculoviruses
encoding mSR-BI-t1 (open symbols) or no receptor (empty
virus, filled triangles) and grown at 27 °C for 6 days.
Cell lysates were prepared in 1.5% octyl glucoside lysis buffer and
reconstituted into liposomes as described under "Experimental
Procedures." The liposomes were incubated with10 µg of protein/ml
of 125I-HDL (squares, triangles) or
[3H]CE-HDL (circles, inverted
triangles) at 37 °C for the indicated times in the presence
(single determinations) or absence (duplicate determinations) of a
40-fold excess of unlabeled HDL, isolated, and washed by filtration,
and the amounts of specific 125I-HDL binding and
[3H]cholesteryl ether uptake were determined as described
under "Experimental Procedures." The nonspecific background values
for 125I-HDL binding to mSR-BI-t1-containing liposomes
ranged from 23 to 48% of the total binding.
|
|

View larger version (19K):
[in this window]
[in a new window]
|
Fig. 4.
Temperature dependence of
125I-HDL association with and [3H]cholesteryl
ether uptake by liposomes reconstituted with mSR-BI-t1-expressing
insect (Sf21) cell lysates. Sf21 cells were infected
with baculoviruses encoding mSR-BI-t1 (bars) or no receptor
(empty virus, not shown) and grown at 27 °C for 6 days. Cell lysates
were prepared in 1.5% octyl glucoside lysis buffer and reconstituted
into liposomes as described under "Experimental Procedures." The
liposomes were incubated with10 µg of protein/ml of
125I-HDL (A) or [3H]CE-HDL
(B) at 37 °C or 0 °C for 2 h in the presence
(single determinations) or absence (duplicate determinations) of a
40-fold excess of unlabeled HDL, isolated, and washed by filtration,
and the amounts of specific 125I-HDL binding and
[3H]cholesteryl ether uptake were determined as described
under "Experimental Procedures." The 100% of control values for
binding and lipid uptake at 37 °C were 3.0 and 13.0 ng of
protein/assay, respectively. The no receptor control lysates binding
and lipid uptake activities at 37 °C were 26 and 9% of those of the
mSR-BI-t1-containing lysates (not shown). The nonspecific background
values for 125I-HDL binding were 48% (37 °C) and 30%
(0 °C) of the total binding. Error bars represent the
range of variation in duplicate determinations.
|
|
To determine if the liposome assay could be used for recombinant SR-BI
produced by mammalian cells, we transfected HEK293S cells with a
mammalian expression vector for mSR-BI-t1 (pACmSR-BI-t1) and isolated a
clone expressing high levels of the receptor, HEK[mSR-BI-t1] (clone
7). Detergent-solubilized lysates of these cells were reconstituted into liposomes, and the binding of 125I-HDL and the uptake
of [3H]cholesteryl ether from [3H]CE-HDL
were measured. Fig. 5A shows
results similar to those seen using extracts from the insect cells,
i.e. high affinity HDL binding (apparent
Kd 8.5 µg of protein/ml,
Bmax 12.8 ng of HDL protein/assay) and selective
lipid uptake (apparent Kd 29.4 µg of protein/ml,
Umax 220.9 ng of HDL protein/assay).

View larger version (38K):
[in this window]
[in a new window]
|
Fig. 5.
125I-HDL association with and
[3H]cholesteryl ether uptake by liposomes reconstituted
with HEK[mSR-BI-t1] or control HEK cell lysates.
HEK[mSR-BI-t1] and control untransfected HEK293S cells were grown in
culture and lysates were prepared in 1.5% octyl glucoside lysis buffer
and reconstituted into liposomes as described under "Experimental
Procedures." A, the mSR-BI-t1-containing liposomes were
incubated with the indicated concentrations of 125I-HDL
(squares) or [3H]CE-HDL (circles)
at 37 °C for 2 h in the presence (single determinations) or
absence (duplicate determinations) of a 40-fold excess of unlabeled
HDL, isolated, and washed by filtration, and the amounts of specific
125I-HDL binding and [3H]cholesteryl ether
uptake were determined as described under "Experimental
Procedures." In the same experiment, the background values for
binding and uptake by control (untransfected HEK293S cell-derived)
liposomes at 10 µg of protein/ml of labeled lipoprotein were 45 and
32% of those of mSR-BI-t1-containing liposomes (not shown). The
nonspecific background values for 125I-HDL binding at 2.5, 5, 10, 25, and 100 µg of protein/ml were 10, 13, 25, 32, and 70% of
total binding, respectively. Inset, expanded scale for
125I-HDL binding. B, the mSR-BI-t1-containing
liposomes were incubated in duplicate with 10 µg of protein/ml of
[3H]CE-HDL at 37 °C for 2 h in the presence of
the indicated amounts of unlabeled lipoprotein competitors, HDL
(open squares), or LDL (filled squares),
isolated, and washed by filtration, and the amounts of
[3H]cholesteryl ether uptake were determined. In the same
experiment, the background values for uptake by control (untransfected
HEK293S cell-derived) liposomes in the absence of competitor or the
presence of 400 µg of protein/ml of either HDL or LDL were 7.7, 7.1, or 6.7 ng of protein/assay, respectively (not shown). C, the
mSR-BI-t1-containing (open bars) or control (filled
bars) liposomes were incubated in triplicate at 37 °C for
2 h with 10 µg of protein/ml of [3H]CE-HDL in the
absence (None) or presence of either 400 µg of protein/ml
of unlabeled HDL, 50 µg/ml blocking antibody KKB-1, or 50 µg/ml
control antibody from preimmune serum. The liposomes were isolated and
washed by filtration, and the amounts of [3H]cholesteryl
ether uptake were determined as described under "Experimental
Procedures." The 100% of control value for lipid uptake in the
absence of inhibitors was 19.1 ng of protein/assay. Error
bars represent the range of variations in the triplicate
determinations.
|
|
The specificity of the receptor's activity in mSR-BI-t1-containing
mammalian cell lysate-reconstituted liposomes was examined by comparing
the abilities of unlabeled HDL and LDL to inhibit [3H]cholesteryl ether uptake from
[3H]CE-HDL (10 µg of protein/ml). Previous studies of
SR-BI expressed in intact cells established that, although LDL can bind
to SR-BI with high affinity, LDL is a poor inhibitor of HDL binding to SR-BI (6, 25). Fig. 5B shows that, as is the case for intact cells, HDL was an effective inhibitor of mSR-BI-t1-mediated lipid uptake activity from [3H]CE-HDL, whereas LDL was less
effective. The [3H]cholesteryl ether uptake from
[3H]CE-HDL (10 µg of protein/ml) by
mSR-BI-t1-containing mammalian cell lysate-reconstituted liposomes was
inhibited by the polyclonal anti-SR-BI antibody KKB-1 to the same
extent as by excess unlabeled HDL (Fig. 5C), whereas uptake
was not inhibited by control pre-immune antibody. Control untransfected
HEK293S cell lysate-reconstituted liposomes exhibited essentially no
[3H]cholesteryl ether uptake activity.
Although the above data support the validity of the liposome assay, we
further tested the assay by determining the receptor activities of
liposomes reconstituted with insect cell lysates containing in place of
mSR-BI-t1 either a mutant form of mSR-BI-t1 or human CD36, another
class B scavenger receptor (5, 19). We have isolated a set of mutant
mSR-BIs, which exhibit altered ligand-binding properties when expressed
in transfected mammalian cells (23, 25). One of these has a double
substitution of arginines for the glutamines at positions 402 and 418 (designated "402R/418R"). This
402R/418R mutant is as effective as wild-type
mSR-BI in functioning as an LDL receptor in transfected mammalian
cells, mediating high affinity LDL binding, uptake of metabolically
active cholesterol from LDL, and efflux of cholesterol to LDL; however,
it has lost most of the corresponding HDL receptor activity exhibited
by the wild-type receptor (23). Lysates from insect cells expressing mSR-BI-t1, the 402R/418R mutant form of
mSR-BI-t1, or no recombinant protein (control) were reconstituted into
liposomes, and the abilities of the liposomes to bind
125I-HDL or 125I-LDL were determined. Fig.
6B shows that, as expected,
the specific binding of 125I-LDL (5 µg of protein/ml) to
the 402R/418R mutant (light gray
bar) was similar to that of mSR-BI-t1 (open bar) and
substantially greater than that of the receptor-free control
(dark filled bar). In contrast, Fig. 6A shows
that the binding of 125I-HDL (5 µg of protein/ml) to the
402R/418R mutant was much lower than that of
mSR-BI-t1 and was not significantly different from that of the
receptor-free control. Because the binding specificities of the whole
insect lysate-reconstituted liposomes reflected the specificities of
the corresponding intact mammalian cells, it seems likely that the
mechanism of SR-BI-mediated lipoprotein binding in the
lysate-reconstituted liposomes is similar to that in intact mammalian
cells.

View larger version (32K):
[in this window]
[in a new window]
|
Fig. 6.
125I-HDL and 125I-LDL
binding by liposomes reconstituted with insect (Sf21) cell
lysates containing mSR-BI-t1 (open bars), the
402R/418R mutant of mSR-BI (light gray
bars), or no recombinant receptor (dark filled
bars). Sf21 cells were infected with
baculoviruses encoding mSR-BI-t1 (open bars), the
402R/418R mutant of mSR-BI (light gray
bars), or no receptor (empty virus, dark filled bars)
and grown at 27 °C. Cell lysates were prepared in 1.5% octyl
glucoside lysis buffer and reconstituted into liposomes as described
under "Experimental Procedures." The liposomes were incubated with
5 µg of protein/ml of 125I-HDL or 125I-LDL in
the presence (single determinations) or absence (duplicate
determinations) of a 40-fold excess of the corresponding unlabeled
lipoprotein at 37 °C for 2 h, isolated, and washed by
filtration, and the amounts of specific125I-HDL
(A) and 125I-LDL (B) binding were
determined as described under "Experimental Procedures." The 100%
of control values for 125I-HDL and 125I-LDL
binding were 6.99 and 6.95 ng of protein/assay, respectively. The
nonspecific background values for 125I-HDL binding were
23% (mSR-BI-t1) and 25% (402R/418R mutant) of
the total binding. Error bars represent the range of
variations in duplicate determinations. *, the range of variation was
~50%.
|
|
CD36 is a class B scavenger receptor that is structurally similar to
SR-BI and shares a number of ligand-binding activities (19, 26, 42,
44). For example, CD36 binds HDL with an affinity similar to that of
mSR-BI (26, 27, 42); however, CD36 cannot mediate efficient selective
uptake of cholesterol from HDL to cells (26, 27). Fig. 2, B
and C show that CD36-containing insect cell
lysate-reconstituted liposomes bound 125I-HDL (filled
squares) at a level comparable to that of the corresponding mSR-BI-t1-containing liposomes (Fig. 2A, open
squares), Bmax ~ 15 ng of protein/assay
(apparent Kd 30.3 µg of protein/ml). In contrast,
the CD36-containing liposomes exhibited almost no [3H]cholesteryl ether uptake from
[3H]CE-HDL (Fig. 2B, filled
circles, Umax ~ 3.5 ng of protein/assay) compared with that of mSR-BI-t1-containing liposomes (Fig.
2A, open circles, Umax ~ 106.3 ng of protein/assay). Thus, the lipid uptake activities of
mSR-BI-t1 and CD36 in whole insect lysate-reconstituted liposomes
reflected their activities when expressed on the surfaces of intact
mammalian cells.
Taken together the data in Figs. 2-6 show that the whole cell
lysate/liposome assay recapitulated many key features of cellular SR-BI-mediated HDL receptor activity: 1) 125I-HDL binding
and [3H]cholesteryl ether uptake from
[3H]CE-HDL were high affinity and saturable (6); 2)
binding reached a steady state more rapidly than lipid uptake (6); 3)
LDL was a poor inhibitor of HDL binding and lipid uptake (6, 25); 4)
lipid transfer was specifically inhibited by an anti-SR-BI blocking
antibody (25); 5) lipid uptake was substantially more temperature-sensitive than binding (34)2; and 6) lipid
transfer occurred via selective uptake (6). Furthermore, in this assay
the activities of a mutant form of SR-BI
(402R/418R) and the homologue CD36 also
recapitulated those in intact cells. Therefore, the reconstituted
liposome system provides a valid assay for the HDL binding and lipid
uptake activities of SR-BI in detergent-solubilized, whole cell lysates.
One-step Immunoaffinity Purification of mSR-BI-t1--
To examine
the function of SR-BI using the reconstituted liposome assay in the
absence of other proteins, we isolated highly purified mSR-BI-t1 from
HEK[mSR-BI-t1] cells using a modified version of the rhodopsin
purification of Reeves et al. (38). The receptor was
purified from octyl glucoside-solubilized cells by immunoaffinity
chromatography using an antibody to its C-terminal rhodopsin peptide
epitope tag. Results of a typical purification are shown in Fig.
7, in which specimens obtained throughout
the procedure were fractionated by SDS-PAGE and visualized by silver staining of the gel. Both the starting cell lysate (lane 1)
and the initial column flow-through (material not retained by the column, lane 2) were highly complex protein mixtures. After
washing the column so that no additional protein was detected by silver staining (lane 3), we eluted bound material with the
rhodopsin C-terminal peptide and recovered virtually homogeneously pure mSR-BI-t1 (lanes 4-8). The electrophoretic mobility of the
bulk of the purified material corresponded to 82 kDa, as expected from previous studies (6). Immunoblotting of a replicate gel with anti-mSR-BI KKB-1 antibody established that the major protein band
detected by silver staining, as well as the very low abundance minor
bands (e.g. see lane 5), was either mSR-BI-t1 or
minor proteolytic or aggregated forms of mSR-BI-t1 (not shown).
Immunoblotting also revealed that a very small amount of mSR-BI-t1 was
present in the column flow-through and wash fractions (corresponding to
lanes 2 and 3, not shown). We estimate from
quantitative immunoblotting that the overall recovery of purified
mSR-BI-t1 from the lysate was ~80%. The yield of mSR-BI-t1 was
100-150 µg/liter of suspension cell culture.

View larger version (25K):
[in this window]
[in a new window]
|
Fig. 7.
Immunoaffinity purification of mSR-BI-t1 from
HEK[mSR-BI-t1] cell lysates. HEK[mSR-BI-t1] cells were grown
in suspension culture and lysed, and the lysates were subjected to
immunoaffinity chromatography using the 1D4 monoclonal anti-C-terminal
epitope tag antibody. The bound protein was eluted from the column with
the peptide epitope as described under "Experimental Procedures."
Samples of the cell lysate, column flow-through (unbound material),
column wash, and peptide-eluted fractions (10 µl of each fraction)
were fractionated by 10% SDS-PAGE, and the proteins in the gel were
visualized using a Bio-Rad silver-staining kit. The mobilities of
molecular weight standards are indicated on the left.
|
|
Activity of Purified mSR-BI-t1 Reconstituted into
Liposomes--
With the availability of pure mSR-BI-t1 and a fully
validated in vitro reconstituted liposome assay, we were
able to address the main question of this study: could mSR-BI,
independently of any other protein, mediate HDL binding and selective
lipid uptake? Fig. 8 shows the results of
an experiment in which we measured as a function of ligand
concentration 125I-HDL binding to (open squares)
and [3H]cholesteryl ether uptake from
[3H]CE-HDL by (open circles) liposomes
reconstituted with the immunoaffinity-purified receptor. Fig. 8
(open squares) shows that specific 125I-HDL
binding was of high affinity (apparent Kd of 11.9 µg of protein/ml) and saturable (Bmax ~ 16.6 ng of protein/assay). The maximal binding, corrected for the amount of
protein incorporated in the liposomes, was 311 ng of protein/µg of
liposome protein, a value 65-fold higher than the corresponding value
for binding of 125I-HDL to liposomes reconstituted with
HEK[mSR-BI-t1] whole cell lysate (Bmax of 4.8 ng of protein/µg of liposome protein). Fig. 8 (open
circles) shows the specific [3H]cholesteryl ether
uptake from [3H]CE-HDL was also high affinity and
saturable. For [3H]cholesteryl ether uptake, the apparent
Kd was 13.8 µg of protein/ml and the
Umax was 134 ng of protein/assay or 2500 ng of
protein/µg of liposome protein. The relative amount of lipid uptake
was substantially greater than that of binding, with a ratio of the
maximal [3H]CE-HDL uptake/125I-HDL binding of
8, clearly showing that the pure receptor mediated selective lipid
uptake from HDL. The HDL binding and lipid uptake activities of the
mSR-BI-t1-containing liposomes increased linearly with the amount of
mSR-BI-t1 incorporated into the liposomes (data not shown).

View larger version (24K):
[in this window]
[in a new window]
|
Fig. 8.
125I-HDL binding and
[3H]CE-HDL uptake by liposomes reconstituted with
immunoaffinity-purified mSR-BI-t1. Immunoaffinity-purified
mSR-BI-t1 isolated from HEK[mSR-BI-t1] cells was reconstituted into
liposomes as described under "Experimental Procedures." Control
liposomes without added receptor were prepared in parallel. The
liposomes were incubated with the indicated concentrations of
125I-HDL (squares or triangles) or
[3H]CE-HDL (circles or inverted
triangles) at 37 °C for 3 h in the presence (single
determinations) or absence (duplicate determinations) of a 40-fold
excess of unlabeled HDL, isolated, and washed by filtration, and the
amounts of specific125I-HDL binding and
[3H]cholesteryl ether uptake were determined as described
under "Experimental Procedures." The binding and lipid uptake
values for the control (no receptor) liposomes (filled
triangles, partially obscured by the squares)
determined at labeled lipoprotein concentrations of 10 µg of
protein/ml were 0.8 and 0.9 ng/assay, respectively. Error
bars represent the range of variations in duplicate
determinations. The nonspecific background values for
125I-HDL binding at 2.5, 10, 25, 70, and 100 µg of
protein/ml were 20, 24, 26, 30, 42, and 50% of total binding,
respectively. Inset, expanded scale for 125I-HDL
binding.
|
|
We conducted three additional experiments to determine if the
selective lipid uptake activity of the purified receptor reconstituted into liposomes exhibited characteristics similar to those of SR-BI in
intact cells. First, we compared the abilities of unlabeled HDL and LDL
to inhibit 125I-HDL binding and
[3H]cholesteryl ether uptake from
[3H]CE-HDL (10 µg of protein/ml). Fig.
9 shows that excess unlabeled HDL
(open squares and circles) effectively inhibited
125I-HDL binding (panel A) and
[3H]cholesteryl ether uptake (panel B),
whereas unlabeled LDL (filled squares and
circles) did not. These results were similar to those observed using liposomes reconstituted with mSR-BI-t1-containing mammalian cell lysates (Fig. 5B) and mSR-BI expressed in
intact mammalian cells (6, 25). We did note that the extent of LDL competition for 125I-HDL binding and
[3H]cholesteryl ether uptake from
[3H]CE-HDL varied somewhat from experiment to experiment
(maximum percent inhibition of 8-20% for binding and 0-25% for
uptake), perhaps reflecting the effects that small changes in the state of the HDL (e.g. oxidation) can have on lipoprotein binding
affinities (41). Second, we tested the anti-SR-BI antibody
KKB-1-specific inhibition of [3H]CE-HDL uptake. Fig.
10 shows that the KKB-1 antibody
inhibited the [3H]cholesteryl ether uptake by
mSR-BI-t1-reconstituted liposomes, but the control antibody from
preimmune serum did not. These results were similar to those obtained
with the mSR-BI-t1 mammalian cell lysate-reconstituted liposomes (Fig.
5C) and mSR-BI transfected intact mammalian cells (25).
Third, we examined the temperature dependence of 125I-HDL
binding to (Fig. 11A) and
[3H]cholesteryl ether uptake from
[3H]CE-HDL (Fig. 11B) at 37 °C (open
bars) or 0 °C (shaded bars). The lower temperature
slightly lowered the125I-HDL binding (4.1 versus
3.3 ng of protein/assay at 37 °C and 0 °C, respectively, 19.5%
reduction), whereas lipid uptake was substantially reduced at the lower
temperature (35.7 versus 14.6 ng of protein/assay at
37 °C and 0 °C, respectively, 59.1% reduction). These findings
were consistent with those obtained with mSR-BI-t1-containing cell
lysate-reconstituted liposomes (Fig. 4) and intact cells (34).2 Thus, SR-BI needed no additional protein co-factors
to allow it to mediate HDL binding and selective cholesteryl ether
uptake.

View larger version (25K):
[in this window]
[in a new window]
|
Fig. 9.
Unlabeled HDL and LDL inhibition of
125I-HDL binding and [3H]CE-HDL uptake by
liposomes reconstituted with immunoaffinity-purified mSR-BI-t1.
Immunoaffinity-purified mSR-BI-t1 isolated from HEK[mSR-BI-t1] cells
was reconstituted into liposomes as described under "Experimental
Procedures." Control liposomes without added receptor were prepared
in parallel. The liposomes were incubated in duplicate with 5 µg of
protein/ml of 125I-HDL (A) or 10 µg of
protein/ml of [3H]CE-HDL (B) in the presence
of the indicated concentrations of unlabeled HDL (open
symbols) or LDL (filled symbols) at 37 °C for 2 h, isolated, and washed by filtration, and the amounts of
125I-HDL binding and [3H]cholesteryl ether
uptake were determined as described under "Experimental
Procedures." The values for the control (no receptor) liposomes
(triangles) determined in the absence of competitor or in
the presence of 400 µg of protein/ml of HDL or LDL were:
125I-HDL binding, 1.98, 0.94, and 1.25 ng/assay,
respectively; and [3H]CE uptake 5.03, 5.34, and 3.93 ng/assay, respectively.
|
|

View larger version (18K):
[in this window]
[in a new window]
|
Fig. 10.
Blocking antibody (KKB-1) inhibition of
[3H]CE-HDL uptake by liposomes reconstituted with
immunoaffinity-purified mSR-BI-t1. Immunoaffinity-purified
mSR-BI-t1 isolated from HEK[mSR-BI-t1] cells was reconstituted into
liposomes as described under "Experimental Procedures." Control
liposomes without added receptor were prepared in parallel. The
liposomes were incubated in triplicate at 37 °C for 2 h with 10 µg of protein/ml of [3H]CE-HDL in the absence ( ) or
presence (+) of unlabeled HDL (400 µg of protein/ml), KKB-1 antibody
(50 µg/ml), or preimmune IgG (50 µg/ml), isolated, and washed by
filtration, and the amounts of [3H]cholesteryl ether
uptake were determined as described under "Experimental
Procedures." The 100% of control value for lipid uptake by the
receptor-containing liposomes in the absence of inhibitors was 39.9 ng
of protein/assay. Error bars represent the range of
variations in triplicate determinations.
|
|

View larger version (23K):
[in this window]
[in a new window]
|
Fig. 11.
Temperature dependence of
125I-HDL association with and [3H]cholesteryl
ether uptake by liposomes reconstituted with immunoaffinity-purified
mSR-BI-t1. Immunoaffinity-purified mSR-BI-t1 isolated from
HEK[mSR-BI-t1] cells was reconstituted into liposomes as described
under "Experimental Procedures." The liposomes were incubated with
10 µg of protein/ml of 125I-HDL (A) or
[3H]CE-HDL (B) at 37 °C (open
bars) or 0 °C (filled bars) for 2 h in the
presence (single determinations) or absence (duplicate determinations)
of a 40-fold excess of unlabeled HDL, isolated, and washed by
filtration, and the amounts of specific 125I-HDL binding
and [3H]cholesteryl ether uptake were determined as
described under "Experimental Procedures." The 100% of control
values for binding and lipid uptake at 37 °C were 4.1 and 35.7 ng of
protein/assay, respectively. The specific values for the control (no
receptor) liposomes determined at 37 °C were: 125I-HDL
binding, 28%; and [3H]CE uptake, ~0% (not shown). The
nonspecific background values for 125I-HDL binding were
24% (37 °C) and 22% (0 °C) of the total binding. Error
bars represent the range of variations in duplicate
determinations.
|
|
 |
DISCUSSION |
We have developed an in vitro reconstituted
liposome assay to measure the ligand binding and lipid transport
activities of detergent-solubilized forms of the HDL receptor SR-BI. An
epitope-tagged form of the recombinant receptor (mSR-BI-t1) in
detergent-solubilized whole insect or mammalian cell lysates, or
mSR-BI-t1 purified by immunoaffinity chromatography essentially to
homogeneity, can be assayed using this liposome system. The liposome
assay recapitulated many features of the HDL receptor activity of SR-BI
expressed in intact cells (5): 1) 125I-HDL binding and
[3H]cholesteryl ether uptake from
[3H]CE-HDL were high affinity and saturable, 2) binding
reached a steady state more rapidly than lipid uptake, 3) LDL, although a tight binding ligand of the receptor, was a poor inhibitor of HDL
binding and lipid uptake from HDL, 4) lipid transfer was
specifically inhibited by an anti-SR-BI blocking antibody, 5)
lipid uptake was substantially more temperature-sensitive than
HDL binding, and 6) lipid transfer occurred via selective
uptake. Furthermore, the novel binding properties of a doubly
mutated receptor (Q402R and Q418R, normal LDL binding with the loss of
HDL binding (23)) were reproduced in the liposome assay, as was the
ability of the SR-BI homologue CD36 to bind HDL but not mediate
efficient lipid uptake (26, 27, 42). It should be possible to use this
assay to explore in detail many features of the mechanism underlying the complex ligand binding and lipid transport activities of SR-BI. It
should be noted that, prior to and after the discovery of SR-BI and its
role as an HDL receptor for selective lipid uptake, several groups
reported that intact, not solubilized, membranes isolated from
adipocyte, steroidogenic, or hepatic tissues or cells could mediate selective lipid uptake (32, 45-49).
The first question regarding the mechanism of SR-BI
activity that we addressed using this assay was: does SR-BI require the cooperation of other proteins to mediate HDL binding and selective lipid uptake, or are these activities autonomous properties of the
receptor (independent of other proteins)? Several observations raised
the possibility that the complex activities mediated by SR-BI might
require the intervention or collaboration of other proteins. For
example, SR-BI can be found in specialized membrane microdomains,
including caveolar-like domains under certain conditions in some
cultured cells (50) and microvillar channels in mammalian steroidogenic
cells in vivo (51, 52). Indeed, SR-BI expression in cultured
cells can induce the formation of microvillar channel-like structures
(43) and plays a role in the formation and/or stability of microvillar
channels in steroidogenic cells in vivo (53, 54). In
addition, SR-BI has been shown to bind, via its C-terminal cytoplasmic
tail, to a multiple PDZ domain-containing scaffold protein called CLAMP
(55). The only unequivocal way to determine if other proteins are
essential for key SR-BI activities was to examine the activity of the
receptor purified away from other proteins. The liposome assay together
with the highly efficient immunoaffinity purification of an epitope
tagged form of the receptor permitted an unequivocal answer to this
question. Essentially homogeneously pure mSR-BI-t1 incorporated into
phosphatidylcholine/cholesterol liposomes did mediate high affinity and
saturable binding of 125I-HDL that was accompanied by
efficient selective uptake of [3H]cholesteryl ether from
[3H]CE-HDL. These findings do not address the question of
whether or not other proteins can or do modulate SR-BI's intrinsic
ability to mediate HDL binding to and selective lipid uptake by intact cells. Neither do they address the role, if any, of lipoprotein internalization by cells in selective uptake. They do, however, establish that SR-BI itself has the capacity to function as an HDL receptor for selective lipid uptake in liposomes without
the required intervention of other proteins or cellular
structures or compartments. Therefore, these results suggest
that SR-BI itself is primarily responsible for the lipid transfer step
during SR-BI-mediated selective lipid uptake in
vivo.
 |
ACKNOWLEDGEMENTS |
We thank M. Penman and S. Xu for help with
lipoprotein preparations and advice regarding assays; T. Nieland and W. Evans for assistance; and X. Gu, B. Trigatti, W. Schneider, A. Rigotti, K. Cha, E. Getmanova, C. Bruel, S. Bell, F. Yang, G. Paradis, and R. Cook for advice and generously providing reagents. We are especially
grateful to P. Reeves and G. Khorana who very generously provided
advice, access to equipment, and assistance in adapting to SR-BI the
procedure for the purification of rhodopsin developed by them and their
colleagues and to Karen Kozarsky for providing the KKB-1 antibody used
in these studies.
 |
FOOTNOTES |
*
This work was supported in part by Grant HL52212 from the
National Institutes of Health.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
Postdoctoral Fellow of the NHLBI, National Institutes of Health.
Current address: NeoGenesis Pharmaceuticals, Inc., Cambridge, MA 02139.
§
To whom correspondence should be addressed: Dept. of Biology,
Massachusetts Institute of Technology, Rm. 68-483, Cambridge, MA 02139. Tel.: 617-253-6793; Fax: 617-258-5851; E-mail: krieger@mit.edu.
Published, JBC Papers in Press, July 10, 2002, DOI 10.1074/jbc.M204265200
2
T. Nieland, T. Kirchhausen, and M. Krieger,
unpublished observations.
 |
ABBREVIATIONS |
The abbreviations used are:
LDL, low density
lipoprotein;
HDL, high density lipoprotein;
SR-BI, scavenger receptor,
class B, type I;
DiI, 1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanime perchlorate;
DiI-HDL, DiI-labeled HDL;
CE, cholesteryl ether;
CE-HDL, CE-labeled
HDL;
PBS, phosphate-buffered saline.
 |
REFERENCES |
| 1.
|
Brown, M. S.,
and Goldstein, J. L.
(1986)
Science
232,
34-47[Free Full Text]
|
| 2.
|
Glass, C.,
Pittman, R. C.,
Weinstein, D. B.,
and Steinberg, D.
(1983)
Proc. Natl. Acad. Sci. U. S. A.
80,
5435-5439[Abstract/Free Full Text]
|
| 3.
|
Stein, Y.,
Dabach, Y.,
Hollander, G.,
Halperin, G.,
and Stein, O.
(1983)
Biochim. Biophys. Acta
752,
98-105[Medline]
[Order article via Infotrieve]
|
| 4.
|
Pieters, M. N.,
Schouten, D.,
and Van Berkel, T. J.
(1994)
Biochim. Biophys. Acta
1225,
125-134[Medline]
[Order article via Infotrieve]
|
| 5.
|
Krieger, M.
(1999)
Annu. Rev. Biochem.
68,
523-558[CrossRef][Medline]
[Order article via Infotrieve]
|
| 6.
|
Acton, S.,
Rigotti, A.,
Landschulz, K. T., Xu, S.,
Hobbs, H. H.,
and Krieger, M.
(1996)
Science
271,
518-520[Abstract]
|
| 7.
|
Kozarsky, K. F.,
Donahee, M. H.,
Rigotti, A.,
Iqbal, S. N.,
Edelman, E. R.,
and Krieger, M.
(1997)
Nature
387,
414-417[CrossRef][Medline]
[Order article via Infotrieve]
|
| 8.
|
Rigotti, A.,
Trigatti, B. L.,
Penman, M.,
Rayburn, H.,
Herz, J.,
and Krieger, M.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
12610-12615[Abstract/Free Full Text]
|
| 9.
|
Trigatti, B.,
Rayburn, H.,
Vinals, M.,
Braun, A.,
Miettinen, H.,
Penman, M.,
Hertz, M.,
Schrenzel, M.,
Amigo, L.,
Rigotti, A.,
and Krieger, M.
(1999)
Proc. Natl. Acad. Sci. U. S. A.
96,
9322-9327[Abstract/Free Full Text]
|
| 10.
|
Mardones, P.,
Quinones, V.,
Amigo, L.,
Moreno, M.,
Miquel, J. F.,
Schwarz, M.,
Miettinen, H. E.,
Trigatti, B.,
Krieger, M.,
VanPatten, S.,
Cohen, D. E.,
and Rigotti, A.
(2001)
J. Lipid Res.
42,
170-180[Abstract/Free Full Text]
|
| 11.
|
Sehayek, E.,
Ono, J. G.,
Shefer, S.,
Nguyen, L. B.,
Wang, N.,
Batta, A. K.,
Salen, G.,
Smith, J. D.,
Tall, A. R.,
and Breslow, J. L.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
10194-10199[Abstract/Free Full Text]
|
| 12.
|
Ji, Y.,
Wang, N.,
Ramakrishnan, R.,
Sehayek, E.,
Huszar, D.,
Breslow, J. L.,
and Tall, A. R.
(1999)
J. Biol. Chem.
274,
33398-33402[Abstract/Free Full Text]
|
| 13.
|
Kozarsky, K. F.,
Donahee, M. H.,
Glick, J. M.,
Krieger, M.,
and Rader, D. J.
(2000)
Arterioscler. Thromb. Vasc. Biol.
20,
721-727[Abstract/Free Full Text]
|
| 14.
|
Ueda, Y.,
Gong, E.,
Royer, L.,
Cooper, P. N.,
Francone, O. L.,
and Rubin, E. M.
(2000)
J. Biol. Chem.
275,
20368-20373[Abstract/Free Full Text]
|
| 15.
|
Arai, T.,
Wang, N.,
Bezouevski, M.,
Welch, C.,
and Tall, A. R.
(1999)
J. Biol. Chem.
274,
2366-2371[Abstract/Free Full Text]
|
| 16.
|
Holm, T. M.,
Braun, A.,
Trigatti, B. L.,
Brugnara, C.,
Sakamoto, M.,
Krieger, M.,
and Andrews, N. C.
(2002)
Blood
99,
1817-1824[Abstract/Free Full Text]
|
| 17.
|
Miettinen, H. E.,
Rayburn, H.,
and Krieger, M.
(2001)
J. Clin. Invest.
108,
1717-1722[CrossRef][Medline]
[Order article via Infotrieve]
|
| 18.
|
Braun, A.,
Trigatti, B. L.,
Post, M. J.,
Sato, K.,
Simons, M.,
Edelberg, J. M.,
Rosenberg, R. D.,
Schrenzel, M.,
and Krieger, M.
(2002)
Circ. Res.
90,
270-276[Abstract/Free Full Text]
|
| 19.
|
Acton, S. L.,
Scherer, P. E.,
Lodish, H. F.,
and Krieger, M.
(1994)
J. Biol. Chem.
269,
21003-21009[Abstract/Free Full Text]
|